[HTML][HTML] Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients

M Cortes-Cerisuelo, SJ Laurie, DV Mathews… - American Journal of …, 2017 - Elsevier
While most human T cells express the CD28 costimulatory molecule constitutively, it is well
known that age, inflammation, and viral infection can drive the generation of CD28 null T
cells. In vitro studies have demonstrated that CD28 null cell effector function is not impacted
by the presence of the CD28 costimulation blocker belatacept. As such, a prevailing
hypothesis suggests that CD28 null cells may precipitate costimulation blockade-resistant
rejection. However, CD28+ cells possess more proliferative and multifunctional capacity …